PHASE 2/3 ADAPTIVE DESIGN, RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DM199 FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE (REMEDY2 TRIAL)
- Registry ID
- DM199-2021-001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- DIAMEDICA INC
- Start date
- 2025-07-21
- Last update
- 2024-11-01
Conditions
Related clinical trials
- OPTIMIZING REPERFUSION TO IMPROVE OUTCOMES AND NEUROLOGIC FUNCTION (ORION): A MULTICENTER,
DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, PARALLEL-GROUP, PHASE 2/3 STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF JX10 IN ACUTE ISCHEMIC STROKE WITH LATE PRESENTATIONS
- A MULTICENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TWOPART, RANDOMIZED, PHASE 2 CLINICAL TRIAL TO ASSESS SAFETY, TOLERABILITY,
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OFBB-031 IN ACUTE ISCHEMIC
STROKE (AIS) PATIENTS
- THE ACT RRCT- ALTEPLASE COMPARED TO TENECTEPLASE IN PATIENTS WITH ACUTE ISCHEMIC STROKE:QUICR & OPTIMISE REGISTRY BASED PRAGMATIC RANDOMIZED CONTROLLED TRIAL
View on source registry